Global roadmap for TB vaccine development launched
The Roadmap identifies priorities for the development and implementation of new TB vaccines with the aim to coordinate and accelerate global action.
On 20 April 2021, the European & Developing Countries
Clinical Trials Partnership (EDCTP) and the Amsterdam Institute
for Global Health and Development (AIGHD) have launched a global
TB vaccine research and development roadmap at the Virtual
Global Forum on TB Vaccines. It identifies priorities for the
development and implementation of new TB vaccines with the aim
to coordinate and accelerate global action. The project was
carried out in close collaboration with the World Health
Organization.
With more than 1.4 million deaths a
year, TB is a major global public health challenge, especially
in low- and middle-income countries. Ambitious global TB control
goals have been established, but it is widely recognised that
these will not be achieved without safe and effective vaccines.
Despite the huge global burden of disease, there is little
commercial incentive to develop new TB vaccines – no new
vaccine has been introduced since bacillus
Calmette-Guérin (BCG) in the 1920s. Addressing the need
for new vaccines will require coordinated cross-sectoral
partnerships and a focus on “end-to-end”
development, from early-stage discovery research through to
programmatic implementation.
For more information and
to access the Roadmap, click
here.
